NF Trinity Capital’s AbbVie ABBV Stock Holding History

NF Trinity Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-48,000	Closed	-$3.13M	–	49
2017 Q1	$3.13M	Hold	48,000	–	–	0.42%	39
2016 Q4	$3.01M	Buy	+48,000	New	+$2.93M	0.42%	40

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NF Trinity Capital's ABBV Position: Q2 2017 in Review

NF Trinity Capital sold out of AbbVie (ABBV) in Q2 2017, closing a stake of 48,000 shares — an estimated $3.13M sold.

NF Trinity Capital first reported a position in ABBV in Q4 2016 and held it in 2 quarters. The position peaked at $3.13M in Q1 2017. 1,763 funds tracked by Wall St. Rank hold ABBV as of Q2 2017.

NF Trinity Capital reported no remaining AbbVie position as of Q2 2017 after selling out during the quarter.
NF Trinity Capital sold 48,000 AbbVie shares in Q2 2017, an estimated $3.13M.
NF Trinity Capital first reported a position in AbbVie in Q4 2016 and held it in 2 quarters.
NF Trinity Capital's AbbVie position peaked at $3.13M in Q1 2017.
1,763 funds tracked by Wall St. Rank held AbbVie as of Q2 2017.

Based on NF Trinity Capital's 13F filing for Q2 2017, filed 8 Aug 2017.